ESTRO Brachytherapy for Prostate Cancer 2018

416 / 884

• 54Gy in 9 fractions
• 112 patients 1996-2005
– 15 LOW RISK
– 29 INTER RISK
– 68 HIGH RISK
– Neoadjuvant hormones in 94
et al